1. Why will customers pay for this instead of using existing tools?

Customers already spend significant budgets on drug discovery software, but today’s tooling is fragmented, expensive, and often constrained to narrow regions of chemical space. QuantumCURE Pro™ addresses these pain points by consolidating core discovery workflows into a single, scalable platform while enabling broader, more diverse exploration without requiring new local infrastructure.

Importantly, this is not about replacing every existing tool overnight. It is about reducing friction, improving throughput, and expanding discovery reach in a way that aligns with how research teams already work and pay for software today.

2. Who is the buyer, and how does purchasing actually happen?

The buyer is typically an institutional decision-maker: a cancer center director, a principal investigator managing a funded program, a biotech R&D lead, or a government lab program manager. These buyers control budgets allocated specifically for discovery tooling, shared computational platforms, or program execution. Purchasing occurs through familiar mechanisms, annual institutional licenses, enterprise software contracts, or program-funded discovery engagements, rather than consumer-style subscriptions. This aligns QuantumCURE Pro™ with established procurement behavior, not experimental buying patterns.

3. How is this defensible against large incumbents?

Defensibility comes from system-level integration and execution, not a single algorithm. QuantumCURE Pro™ combines cloud-orchestrated discovery workflows, entropy-enhanced exploration, proprietary symbolic representations, and program-scale execution into a unified platform that is difficult to replicate without significant engineering effort and domain expertise.

Large incumbents are optimized for selling established workflows to existing customers. QuantumLaso is optimized for building and evolving infrastructure that lowers cost barriers and enables new discovery modes, creating a different execution and adoption profile.

4. What proof exists that the system works beyond theory?

The platform has already been validated through industry-standard benchmarks and internal rediscovery tests using known drug–target pairs. These tests demonstrate that QuantumCURE Pro™ produces accurate, reproducible results while operating at scale in a cloud environment.

Beyond benchmarks, the system is actively being prepared for continuous, real-world discovery runs, generating ranked compound outputs suitable for downstream validation. This is a working engine, not a conceptual prototype.

5. What does success look like in the next 12–24 months?

Success is defined by measurable execution milestones, not abstract vision. In the next 12–24 months, this includes securing paid pilot engagements, converting early adopters into institutional licenses, and achieving several million dollars in annual recurring revenue. Equally important is demonstrating operational maturity: stable cloud deployment, repeatable discovery workflows, and documented outcomes that support expansion into additional institutions and programs.

6. How big can this get without becoming a pharma company?

QuantumLaso is not pursuing clinical development or wet-lab operations. The company remains focused on being a discovery platform provider, enabling others to advance compounds downstream. This allows the business to scale through software licenses, enterprise deployments, and program-based discovery partnerships without assuming the capital intensity, regulatory burden, or risk profile of a pharmaceutical company.

7. What is the go-to-market motion, and how long is the sales cycle?

The initial go-to-market strategy focuses on targeted pilots and institutional licenses, not broad outbound sales. Early engagements are expected to close in the 3–6 month range, consistent with academic and enterprise research procurement cycles. Program-based discovery engagements may have longer lead times but offer higher-value contracts and deeper integration, balancing near-term revenue with long-term strategic positioning.

8. How dependent is the platform on quantum hardware availability?

QuantumCURE Pro™ is fully functional today using classical compute and quantum random number generation. Quantum hardware is treated as an optional entropy source and future enhancement, not a dependency. This ensures the platform delivers immediate value while remaining positioned to incorporate advances in quantum computing as they become commercially viable.

9. What are the biggest execution risks, and how are they mitigated?

The primary risks are execution bandwidth, adoption pacing, and managing program-based work alongside SaaS growth. These are mitigated through a staged rollout strategy, conservative revenue projections, and a focus on capital efficiency. Importantly, the system is already built and operational, reducing technical risk relative to early-stage discovery platforms that are still in development.

10. What would make this an attractive acquisition target?

QuantumCURE Pro™ becomes attractive to acquirers as it demonstrates durable institutional ARR, strong renewal behavior, and strategic leverage, either by accelerating discovery timelines, reducing internal costs, or enabling new exploration modes. Acquisitions in this space are typically driven by recurring revenue combined with the cost and risk of internal replication. The platform is being built to meet that profile, while remaining valuable as a standalone business.

​

Mansour Ansari

Founder: QuantumLaso, LLC

February 2026

Email: videomover@gmail.com